Notice of Application - 2012
[Federal Register Volume 77, Number 123 (Tuesday, June 26, 2012)]
[Notices]
[Page 38086]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-15613]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application;
Chattem Chemicals Inc.
Pursuant to Sec. 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on May 16, 2012,
Chattem Chemicals Inc., 3801 St. Elmo
Avenue, Chattanooga, Tennessee 37409,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
| Drug |
Schedule |
| Gamma Hydroxybutyric Acid (2010) |
I |
| 4-Methoxyamphetamine (7411) |
I |
| Dihydromorphine (9145) |
I |
| Amphetamine (1100) |
II |
| Methamphetamine (1105) |
II |
| Lisdexamfetamine (1205) |
II |
| Methylphenidate (1724) |
II |
| Pentobarbital (2270) |
II |
| Codeine (9050) |
II |
| Dihydrocodeine (9120) |
II |
| Oxycodone (9143) |
II |
| Hydromorphone (9150) |
II |
| Hydrocodone (9193) |
II |
| Meperidine (9230) |
II |
| Methadone (9250) |
II |
| Methadone intermediate (9254) |
II |
| Morphine (9300) |
II |
| Oripavine (9330) |
II |
| Thebaine (9333) |
II |
| Opium tincture (9630) |
II |
| Opium, powdered (9639) |
II |
| Opium, granulated (9640) |
II |
| Oxymorphone (9652) |
II |
| Noroxymorphone (9668) |
II |
| Alfentanil (9737) |
II |
| Remifentanil (9739) |
II |
| Sufentanil (9740) |
II |
| Tapentadol (9780) |
II |
| Fentanyl (9801) |
II |
The company plans to manufacture
the listed controlled substances in bulk
for distribution and sale to its
customers. Regarding (9640) the
company plans to manufacture another
controlled substance for sale to its
customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than August 27, 2012.
Dated: June 18, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–15618 Filed 6–25–12; 8:45 am]
BILLING CODE 4410–09–P
NOTICE: This is an unofficial version. An official version of this publication may be obtained
directly from the Government Printing Office (GPO). |
